{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"    \ud83d\udc41\ufe0f GLP-1. Vision. Vigilance: The Hidden Ocular Signal of Dulaglutide","description":"\ud83d\udc41\ufe0f New NEJM correspondence highlights a potentially important ophthalmic signal linked to dulaglutide therapy. Two patients developed choroidal lymphoid hyperplasia with painless visual loss within months of GLP-1 receptor agonist initiation. Remarkably, ocular and systemic findings rapidly resolved after stopping dulaglutide. As GLP-1 therapies expand across diabetes, obesity, and cardiometabolic medicine, clinicians should remain vigilant for emerging ocular adverse events. A fascinating intersection of endocrinology, immunology, and ophthalmology. \ud83d\udd2c\ud83d\udc89\ud83d\udc53 #NEJM #GLP1 #Dulaglutide #Ophthalmology #Diabetes #Retina #Cardiology #ObesityMedicine #PrecisionMedicine #MedicalEducation ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41315505\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/202009545"}